496 related articles for article (PubMed ID: 35661166)
1. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
3. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
4. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
[TBL] [Abstract][Full Text] [Related]
6. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Moreau P; Mateos MV; Gonzalez Garcia ME; Einsele H; De Stefano V; Karlin L; Lindsey-Hill J; Besemer B; Vincent L; Kirkpatrick S; Delforge M; Perrot A; van de Donk NWCJ; Pawlyn C; Manier S; Leleu X; Martinez-Lopez J; Ghilotti F; Diels J; Morano R; Albrecht C; Strulev V; Haddad I; Pei L; Kobos R; Smit J; Slavcev M; Marshall A; Weisel K
Adv Ther; 2024 Feb; 41(2):696-715. PubMed ID: 38110653
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
10. Teclistamab: Mechanism of action, clinical, and translational science.
Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
[TBL] [Abstract][Full Text] [Related]
11. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
12. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
13. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
14. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
15. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H
Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117
[TBL] [Abstract][Full Text] [Related]
16. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
18. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
19. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
[TBL] [Abstract][Full Text] [Related]
20. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
